Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats
| Autor: | Maria Kolpakova, Irina Filchenko, Anna Simanenkova, Svetlana Chefu, Timur D. Vlasov |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Blood Glucose
Male 0301 basic medicine medicine.medical_specialty Endocrinology Diabetes and Metabolism Neuroprotection Glucagon-Like Peptide-1 Receptor Diabetes Mellitus Experimental 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus Internal Medicine medicine Animals Hypoglycemic Agents Rats Wistar Receptor Glucagon-like peptide 1 receptor Liraglutide business.industry Brain Type 2 Diabetes Mellitus medicine.disease Glucagon-like peptide-1 Metformin Neuroprotective Agents 030104 developmental biology Endocrinology Diabetes Mellitus Type 2 Ischemic Attack Transient Cardiology and Cardiovascular Medicine business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Diabetes and Vascular Disease Research. 15:567-570 |
| ISSN: | 1752-8984 1479-1641 |
| Popis: | Objective: Stroke is a severe complication of type 2 diabetes mellitus. Glucagon-like peptide-1 receptor agonists have been shown to have a neuroprotective effect in experimental diabetes. The aim of this study was to determine if their neuroprotective effect is an independent property of the drug independent of glycaemic control. Methods: This two-phase study used male Wistar rats. In the first phase, experimental animals were pretreated with liraglutide, while controls received only vehicle. After transient focal brain ischaemia modelling, neurological deficit and brain infarct volume were measured. In the second phase, the first and the second groups of experimental animals with type 2 diabetes mellitus received liraglutide and metformin, respectively, while control animals with diabetes received only vehicle. After transient focal brain ischaemia modelling, neurological deficit and brain infarct volume were evaluated. Results: Pretreatment with liraglutide in diabetic and non-diabetic animals reduced infarct size as compared to controls, while only non-diabetic liraglutide-treated rats presented neurologic deficit decreases. Despite glycaemia normalization, metformin-treated diabetic rats had no differences in stroke outcome when compared to the control group. Conclusion: The neuroprotective effect of liraglutide is not associated with glycaemic control amelioration in experimental type 2 diabetes mellitus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|